Category: Zepbound
-
Zepbound (tirzepatide) superior to Wegovy (semaglutide), says Lilly-funded clinical trial
•
In the midst of the war on obesity, a clear winner has emerged in the battle between two weight-loss injections. Zepbound (tirzepatide), made by Fortune 500 company Eli Lilly & Co., outperformed competitor Wegovy (semaglutide), a Novo Nordisk Top 500 product, in a recent study Randomized clinical trial Supported by…
-
Hims & Hers Health declines as Lilly launches single-dose vials of Zepbound By Investing.com
•
Shares of Hims & Hers Health fell more than 6% Tuesday morning in response to Eli Lilly’s (NYSE:) latest announcement. Lilly announced that it has launched single-dose vials of its obesity drug, Zebound, at a 50% discount to other incretins, a move that comes amid growing competition in the obesity…